文献速递银屑病与炎症性皮肤病

阿达木单抗、乌司奴单抗和苏金单抗在银屑病患者中的药物生存率:BADBIR前瞻性队列研究

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
PubMed 文献 · Br J Dermatol · 2020-03-30

该研究基于英国BADBIR注册库2007年11月至2019年8月的前瞻性队列,纳入9652例银屑病患者,评估阿达木单抗、乌司奴单抗和苏金单抗的药物生存率。结果显示苏金单抗与乌司奴单抗生存率相似且较高,阿达木单抗较低;银屑病关节炎和既往生物制剂暴露对三种药物停药的影响不同。

要点

  • 苏金单抗与乌司奴单抗的持续药物生存率相似,阿达木单抗较低。
  • 银屑病关节炎对阿达木单抗和苏金单抗的生存有保护作用,对乌司奴单抗则预测停药。
  • 既往生物制剂暴露对乌司奴单抗和苏金单抗预测停药,对阿达木单抗预测生存。

核心结论

  • 苏金单抗和乌司奴单抗具有相似的持续药物生存率,而阿达木单抗在银屑病患者中的药物生存率较低。
  • 银屑病关节炎和既往生物制剂暴露是预测因素,且在不同生物制剂间效应不同。

研究设计与样本

  • 研究为前瞻性队列研究,数据来自英国皮肤科医师协会生物制剂和免疫调节剂注册库(BADBIR),时间范围为2007年11月至2019年8月。
  • 采用生存分析并拟合柔性参数生存模型,分析因无效而停用生物制剂的情况。

临床怎么用

  • 在银屑病生物制剂选择中,可参考药物生存率数据,苏金单抗和乌司奴单抗可能具有更优的持续生存。
  • 银屑病关节炎和既往生物制剂暴露史可作为个体化选择生物制剂的参考因素,因其对不同药物的停药风险影响不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. OBJECTIVES: (i) To assess the relative drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis. (ii) To investigate predictors of biologic drug survival. METHODS: A prospective cohort study was performed in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2019. We performed survival analysis and fitted a flexible parametric survival model for biologic discontinuation due to ineffectiveness. RESULTS: In total 9652 patients were included: 5543 starting on adalimumab (57·4%), 991 on secukinumab (10·3%) and 3118 on ustekinumab (32·3%). The overall drug survivals of adalimumab, secukinumab and ustekinumab in year 1 were 0·78 [95% confidence interval (CI) 0·77-0·79], 0·88 (95% CI 0·86-0·91) and 0·88 (95% CI 0·87-0·89), respectively. The adjusted hazard ratios (adjHRs) for discontinuation of adalimumab and secukinumab compared with ustekinumab were 2·11 (95% CI 1·76-2·54) and 0·67 (95% CI 0·40-1·11), respectively. The presence of psoriatic arthritis predicted for survival in the adalimumab and secukinumab cohorts (adjHR 0·67, 95% CI 0·51-0·88 and 0·70, 95% CI 0·40-1·24, respectively), but for discontinuation in the ustekinumab cohort (adjHR 1·42, 95% CI 1·12-1·81). Previous exposure to biologic therapies predicted for discontinuation in the ustekinumab and secukinumab cohorts (adjHR 1·54, 95% CI 1·26-1·89 and 1·49, 95% CI 0·91-2·45, respectively) and for survival in the adalimumab cohort (adjHR 0·71, 95% CI 0·55-0·92). CONCLUSIONS: Secukinumab and ustekinumab have similar sustained drug survival, while adalimumab has a lower drug survival in patients with psoriasis. Psoriatic arthritis and previous biologic experience were predictors with differential effects between the biologic therapies. What is already known about this topic? There is conflicting evidence over the real-world drug survival of secukinumab in patients with psoriasis. Data from registries to date suggest that secukinumab has a lower drug survival than that reported from clinical trials. What does this study add? This study found that secukinumab and ustekinumab had similar sustained drug survival in the real world, while the drug survival of adalimumab was lower, suggesting that the real-world drug survival of secukinumab is higher than previously reported. We found that psoriatic arthritis and previous biologic experience had differential effects on drug discontinuation in the three biologic cohorts. These predictors may help patients and clinicians choose the most appropriate biologic therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020. PMID: 32124442. doi:10.1111/bjd.18981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。